Press Release: Lilly : OrderlyMeds' Response to Eli Lilly's Cease-and-Desist Letter
ATLANTA, April 11, 2025 /PRNewswire/ --Â On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open...
Read full article »
Lilly is a Massachusetts-based pharmaceutical company that develops, produces and markets pharmaceutical products for healthcare professionals, patients and consumers.
Read more